Critical function for nuclear envelope protein TMEM209 in human pulmonary carcinogenesis.

Therapeutic targets for more effective and less toxic treatments of lung cancer remain important. Here we report the identification of the integral nuclear envelope protein TMEM209 as a critical driver of human lung cancer growth and survival. TMEM209 expression was normally limited to testis, but we found that it was widely expressed in lung cancer, in which it localized to the nuclear envelope, Golgi apparatus, and the cytoplasm of lung cancer cells. Ectopic overexpression of TMEM209 promoted cell growth, whereas TMEM209 attenuation was sufficient to block growth. Mass spectrometric analysis identified the nucleoporin protein NUP205 as a TMEM209-interacting protein, stabilizing NUP205 and increasing the level of c-Myc in the nucleus. Taken together, our findings indicate that TMEM209 overexpression and TMEM209-NUP205 interaction are critical drivers of lung cancer proliferation, suggesting a promising new target for lung cancer therapy.

[1]  F. Dammacco,et al.  Targeted therapies in cancer , 2018, Surgery (Oxford).

[2]  Yusuke Nakamura,et al.  Chondrolectin Is a Novel Diagnostic Biomarker and a Therapeutic Target for Lung Cancer , 2011, Clinical Cancer Research.

[3]  Y. Miyagi,et al.  Identification of Epstein-Barr Virus–Induced Gene 3 as a Novel Serum and Tissue Biomarker and a Therapeutic Target for Lung Cancer , 2011, Clinical Cancer Research.

[4]  Yusuke Nakamura,et al.  Characterization of a Cleavage Stimulation Factor, 3′ pre-RNA, Subunit 2, 64 kDa (CSTF2) as a Therapeutic Target for Lung Cancer , 2011, Clinical Cancer Research.

[5]  André Hoelz,et al.  The structure of the nuclear pore complex. , 2011, Annual review of biochemistry.

[6]  Yusuke Nakamura,et al.  A novel tumor‐associated antigen, cell division cycle 45‐like can induce cytotoxic T‐lymphocytes reactive to tumor cells , 2011, Cancer science.

[7]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[8]  J. Soh,et al.  Molecular biology of lung cancer , 2010 .

[9]  Yusuke Nakamura,et al.  Molecular and Cellular Pathobiology Cancer Research Phosphorylation and Activation of Cell Division Cycle Associated 5 by Mitogen-Activated Protein Kinase Play a Crucial Role in Human Lung Carcinogenesis , 2010 .

[10]  Y. Miyagi,et al.  Molecular and Cellular Pathobiology Cancer Research Wnt Inhibitor Dickkopf-1 as a Target for Passive Cancer Immunotherapy , 2010 .

[11]  Lan Xu,et al.  Specific Nucleoporin Requirement for Smad Nuclear Translocation , 2010, Molecular and Cellular Biology.

[12]  Yusuke Nakamura,et al.  The forkhead box M1 transcription factor as a candidate of target for anti‐cancer immunotherapy , 2009, International journal of cancer.

[13]  Yusuke Nakamura,et al.  Activation of WD Repeat and High-Mobility Group Box DNA Binding Protein 1 in Pulmonary and Esophageal Carcinogenesis , 2009, Clinical Cancer Research.

[14]  Y. Miyagi,et al.  Identification of nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer. , 2009, Cancer research.

[15]  Yusuke Nakamura,et al.  Vaccination with multiple peptides derived from novel cancer‐testis antigens can induce specific T‐cell responses and clinical responses in advanced esophageal cancer , 2009, Cancer science.

[16]  Yusuke Nakamura,et al.  HJURP Is a Cell-Cycle-Dependent Maintenance and Deposition Factor of CENP-A at Centromeres , 2009, Cell.

[17]  Yusuke Nakamura,et al.  Involvement of Epithelial Cell Transforming Sequence-2 Oncoantigen in Lung and Esophageal Cancer Progression , 2009, Clinical Cancer Research.

[18]  Yusuke Nakamura,et al.  HLA‐A2‐restricted CTL epitopes of a novel lung cancer‐associated cancer testis antigen, cell division cycle associated 1, can induce tumor‐reactive CTL , 2008, International journal of cancer.

[19]  Yusuke Nakamura,et al.  Detection of novel cancer‐testis antigen‐specific T‐cell responses in TIL, regional lymph nodes, and PBL in patients with esophageal squamous cell carcinoma , 2008, Cancer Science.

[20]  Yusuke Nakamura,et al.  Activation of Placenta-Specific Transcription Factor Distal-less Homeobox 5 Predicts Clinical Outcome in Primary Lung Cancer Patients , 2008, Clinical Cancer Research.

[21]  Yusuke Nakamura,et al.  From cancer genomics to thoracic oncology: discovery of new biomarkers and therapeutic targets for lung and esophageal carcinoma , 2008, General thoracic and cardiovascular surgery.

[22]  Y. Miyagi,et al.  Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas. , 2007, Cancer research.

[23]  Yusuke Nakamura,et al.  Fibroblast growth factor receptor 1 oncogene partner as a novel prognostic biomarker and therapeutic target for lung cancer , 2007, Cancer science.

[24]  Yusuke Nakamura,et al.  Activation of KIF4A as a Prognostic Biomarker and Therapeutic Target for Lung Cancer , 2007, Clinical Cancer Research.

[25]  Yusuke Nakamura,et al.  Identification of human leukocyte antigen‐A24‐restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy , 2007, Cancer science.

[26]  Yusuke Nakamura,et al.  Activation of Holliday junction recognizing protein involved in the chromosomal stability and immortality of cancer cells. , 2007, Cancer research.

[27]  Yusuke Nakamura,et al.  Phosphorylation and activation of cell division cycle associated 8 by aurora kinase B plays a significant role in human lung carcinogenesis. , 2007, Cancer research.

[28]  Y. Miyagi,et al.  Dikkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas. , 2007, Cancer research.

[29]  M. Moran,et al.  Large-scale mapping of human protein–protein interactions by mass spectrometry , 2007, Molecular systems biology.

[30]  Yusuke Nakamura,et al.  Identification of Myc-associated protein with JmjC domain as a novel therapeutic target oncogene for lung cancer , 2007, Molecular Cancer Therapeutics.

[31]  Yusuke Nakamura,et al.  Increased Expression of Insulin-like Growth Factor-II Messenger RNA–Binding Protein 1 Is Associated with Tumor Progression in Patients with Lung Cancer , 2007, Clinical Cancer Research.

[32]  山吹 匠.  Dickkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas , 2007 .

[33]  Yusuke Nakamura,et al.  Activation of CDCA1-KNTC2, members of centromere protein complex, involved in pulmonary carcinogenesis. , 2006, Cancer research.

[34]  Yusuke Nakamura,et al.  The neuromedin U-growth hormone secretagogue receptor 1b/neurotensin receptor 1 oncogenic signaling pathway as a therapeutic target for lung cancer. , 2006, Cancer research.

[35]  Yusuke Nakamura,et al.  Gene expression profiles of small-cell lung cancers: molecular signatures of lung cancer. , 2006, International journal of oncology.

[36]  Yusuke Nakamura,et al.  Characterization of SEZ6L2 cell‐surface protein as a novel prognostic marker for lung cancer , 2006, Cancer science.

[37]  Yusuke Nakamura,et al.  Expression profiles of metastatic brain tumor from lung adenocarcinomas on cDNA microarray. , 2006, International journal of oncology.

[38]  Kevin Carroll,et al.  Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) , 2005, The Lancet.

[39]  M. Eilers,et al.  Transcriptional regulation and transformation by Myc proteins , 2005, Nature Reviews Molecular Cell Biology.

[40]  M. Pegram,et al.  Epidermal growth factor receptor and signal transduction: potential targets for anti-cancer therapy. , 2005, Anti-cancer drugs.

[41]  R. Wozniak,et al.  Vertebrate Nup53 interacts with the nuclear lamina and is required for the assembly of a Nup93-containing complex. , 2005, Molecular biology of the cell.

[42]  N. Normanno,et al.  Targeted therapies and non-small cell lung cancer: methodological and conceptual challenge for clinical trials , 2005, Current opinion in oncology.

[43]  Yusuke Nakamura,et al.  Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). , 2004, Human molecular genetics.

[44]  John R Yates,et al.  Nuclear Membrane Proteins with Potential Disease Links Found by Subtractive Proteomics , 2003, Science.

[45]  S. R. Wente,et al.  Peering through the pore: nuclear pore complex structure, assembly, and function. , 2003, Developmental cell.

[46]  Yusuke Nakamura,et al.  Genome-wide analysis of organ-preferential metastasis of human small cell lung cancer in mice. , 2003, Molecular cancer research : MCR.

[47]  Yusuke Nakamura,et al.  Expression profiles of non-small cell lung cancers on cDNA microarrays: Identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs , 2003, Oncogene.

[48]  David Harrington,et al.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.

[49]  J. Crowley,et al.  Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  M. Mann,et al.  Nup93, a vertebrate homologue of yeast Nic96p, forms a complex with a novel 205-kDa protein and is required for correct nuclear pore assembly. , 1997, Molecular biology of the cell.

[51]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.